Data_Sheet_6_Acceptance of a third COVID-19 vaccine dose, vaccine interchangeability, and clinical trial enrolment among parents of children 12–17 years in Lima, Perú.docx

ObjectivesTo characterize factors associated with parental willingness for their children participation in a COVID-19 vaccine trial, use of different COVID-19 vaccines and acceptance of a third vaccine dose.
MethodsParents of children aged 12–17 years in Lima, Perú were asked to complete an online questionnaire via social networks, from November 9, 2021, to April 23, 2022. We calculated crude and adjusted prevalence ratios with 95% confidence intervals to compare factors with the mentioned outcomes.
ResultsFrom 523 parents responding, 374 completed the survey. 90.4% would give their children a third vaccine dose, 36.6% would allow their children participation in a COVID-19 vaccine clinical trial, and 33.2% would accept different vaccine brands between doses. Parental belief that COVID-19 vaccine studies met quality standards was associated with acceptance of a third booster dose (adjusted PR 3.25; 95% CI1.57–6.74; p = 0.002), enrolment in a COVID-19 clinical trial (adjusted PR 4.49; 95% CI1.25–16.06; p = 0.02), and acceptance of different COVID-19 vaccine brands between doses (adjusted PR 10.02; 95% CI1.40–71.95; p = 0.02).
ConclusionMost parents would accept a third vaccine booster dose, approximately a third would participate in COVID-19 vaccine trials. Believing COVID-19 vaccines studies fulfilled quality standards was associated with the study outcomes. It is necessary to inform about the rigorous processes for the development of COVID-19 vaccines to generate confidence in parents to accept these vaccine-related outcomes.

研究目标：本研究旨在明确与家长是否愿意让子女参与新冠疫苗临床试验、接种不同类型新冠疫苗，以及接受第三剂疫苗接种相关的影响因素。
研究方法：本研究于2021年11月9日至2022年4月23日期间，通过社交网络向秘鲁利马市12至17岁儿童的家长发放线上调查问卷。我们计算了粗患病率比及调整后患病率比，并辅以95%置信区间，以分析各因素与前述研究结局的关联。
研究结果：本次调研共收到523份家长回复，其中374份为有效完成的问卷。结果显示，90.4%的家长愿意让子女接种第三剂疫苗，36.6%的家长同意子女参与新冠疫苗临床试验，33.2%的家长接受在不同针次间接种不同品牌的新冠疫苗。家长认为新冠疫苗研究符合质量标准这一认知，与子女接种第三剂加强针的意愿（调整后患病率比3.25；95%置信区间1.57~6.74；p=0.002）、参与新冠疫苗临床试验的意愿（调整后患病率比4.49；95%置信区间1.25~16.06；p=0.02），以及接受不同品牌新冠疫苗混种的意愿（调整后患病率比10.02；95%置信区间1.40~71.95；p=0.02）均存在显著统计学关联。
研究结论：绝大多数家长愿意让子女接种第三剂新冠疫苗加强针，约三分之一的家长同意子女参与新冠疫苗临床试验。家长认可新冠疫苗研究符合质量标准，与本研究的各项结局均存在关联。未来需向家长普及新冠疫苗研发的严谨流程，以提升其对疫苗相关防疫措施的接受度与信任度。